secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001576280-23-000186
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q3 revenue $143M (+22% YoY); raises FY 2023 guidance to $553-556M
--------------------------------------------------------------------------------

- GAAP net loss $86.1M ($0.73/share) vs $162M ($1.58) YoY; non-GAAP loss $79.2M ($0.67).
- Clinical test volume 43,900 (+35% YoY); biopharma tests 7,500 (+11%).
- Precision oncology revenue up 31% YoY; Medicare appeal payment of $3.6M included.
- FY 2023 revenue guidance raised to $553-556M (23-24% growth); cash $1.2B.
- Launched Guardant360 in Japan/China; Japan approval as CDx for ENHERTU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/0001576280-23-000186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/gh-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001576280-23-000186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer